Who are ChimeriVax-JE, Japanese Encephalitis vaccine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): ChimeriVax™-JE, JE-CV Vaccine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/chimerivax-je-japanese-encephalitis-vaccine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

ChimeriVax-JE, Japanese Encephalitis vaccine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ChimeriVax-JE, Japanese Encephalitis vaccine (ChimeriVax-JE, Japanese Encephalitis vaccine) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Live attenuated chimeric vaccine. Area: Infectious Disease / Immunology.

phase 3 Live attenuated chimeric vaccine Infectious Disease / Immunology Biologic Live · refreshed every 30 min

Target snapshot

ChimeriVax-JE, Japanese Encephalitis vaccine (ChimeriVax-JE, Japanese Encephalitis vaccine) — Sanofi. ChimeriVax-JE is a live attenuated chimeric vaccine that uses a yellow fever virus backbone expressing Japanese encephalitis virus envelope proteins to induce protective immunity against Japanese encephalitis.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
ChimeriVax-JE, Japanese Encephalitis vaccine TARGET	ChimeriVax-JE, Japanese Encephalitis vaccine	Sanofi	phase 3	Live attenuated chimeric vaccine
ChimeriVax™-JE	ChimeriVax™-JE	Sanofi	phase 3	Live attenuated chimeric vaccine
JE-CV Vaccine	JE-CV Vaccine	Sanofi Pasteur, a Sanofi Company	phase 3	Live attenuated chimeric vaccine	Japanese encephalitis virus and dengue virus (serotypes 1-4) structural antigens

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Live attenuated chimeric vaccine class)

Sanofi · 2 drugs in this class
Sanofi Pasteur, a Sanofi Company · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ChimeriVax-JE, Japanese Encephalitis vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/chimerivax-je-japanese-encephalitis-vaccine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab